- Home
- UROY vs SLN Comparison
UROY vs SLN Comparison
Compare UROY & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- SLN
- Stock Information
- Founded
- UROY 2017
- SLN 1994
- Country
- UROY Canada
- SLN United Kingdom
- Employees
- UROY N/A
- SLN N/A
- Industry
- UROY
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- SLN Health Care
- Exchange
- UROY Nasdaq
- SLN Nasdaq
- Market Cap
- UROY 336.8M
- SLN 273.9M
- IPO Year
- UROY N/A
- SLN N/A
- Fundamental
- Price
- UROY $2.49
- SLN $5.52
- Analyst Decision
- UROY Strong Buy
- SLN Buy
- Analyst Count
- UROY 2
- SLN 5
- Target Price
- UROY $4.00
- SLN $32.60
- AVG Volume (30 Days)
- UROY 4.0M
- SLN 111.1K
- Earning Date
- UROY 07-23-2025
- SLN 08-14-2025
- Dividend Yield
- UROY N/A
- SLN N/A
- EPS Growth
- UROY N/A
- SLN N/A
- EPS
- UROY N/A
- SLN N/A
- Revenue
- UROY $15,984,827.00
- SLN $27,701,000.00
- Revenue This Year
- UROY N/A
- SLN N/A
- Revenue Next Year
- UROY N/A
- SLN N/A
- P/E Ratio
- UROY $435.94
- SLN N/A
- Revenue Growth
- UROY N/A
- SLN N/A
- 52 Week Low
- UROY $1.43
- SLN $1.97
- 52 Week High
- UROY $3.12
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- UROY 58.84
- SLN 51.96
- Support Level
- UROY $2.38
- SLN $5.33
- Resistance Level
- UROY $2.54
- SLN $6.05
- Average True Range (ATR)
- UROY 0.12
- SLN 0.44
- MACD
- UROY -0.00
- SLN -0.06
- Stochastic Oscillator
- UROY 73.68
- SLN 38.66
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.